Visual Abstract

Aim: To study potential factors associated with improved glycemic control in PWT1D switching from QD or twice-daily (BID) basal insulin (BI) to QD Gla-300.

Methods: Data from PWT1D in the European REALI pooled database who switched to Gla-300 were analyzed by multivariable ANCOVA to determine factors related to HbA1c change from baseline (BL) to 6 months (6 M) post-treatment. Variables with p<0.10 in the final model were retained.

Results: A total of 455 PWT1D (TOUJEO-NEO, N=397; OPTIMIZE, N=58) were pooled, of whom 436 received Gla-300. Mean age was 50.0±14.7 years and median (Q1, Q3) diabetes duration was 18.0 (10.0, 27.0) years. Almost half of PWT1D (47.3%) presented with ≥1 cardiovascular disease/risk factor and 16.7% with diabetes complications. Mean±SD BL HbA1c was 8.3±0.84%; and change from BL to 6 M was -0.43±0.81%. A total of 179/427 (41.9%) PWT1D received BID BI, 39.1% used Gla-100, and overall mean±SD BI dose was 30.4±17.8 U/day. High BL HbA1c (p<0.0001), prior non-insulin glucose-lowering agent (p=0.027), and absence of diabetes complications (p=0.058) were associated with greater reductions in HbA1c, but not prior BID BI regimen (Table).

Conclusion: Likelihood of achieving clinically important HbA1c reduction in PWT1D switched to QD Gla-300 was mostly dependent on BL HbA1c, and not on previous BID BI regimen.

graphic
View largeDownload slide
Disclosure

D. Müller-wieland: Advisory Panel; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, MSD Corporation, Novo Nordisk, Sanofi, Consultant; Self; Bayer AG, Speaker’s Bureau; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, MSD Corporation, Novo Nordisk, Sanofi. P. Gourdy: Advisory Panel; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk, Sanofi, Research Support; Self; Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Sanofi. R. C. Bonadonna: Advisory Panel; Self; Sanofi, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company. N. Freemantle: Consultant; Self; AstraZeneca, Research Support; Self; ALK, Altimmune, Ipsen Biopharmaceuticals, Inc., Sanofi, Speaker’s Bureau; Self; Novo Nordisk. G. Bigot: None. C. Jamoul: None. A. Ciocca: Employee; Self; Sanofi. M. Bonnemaire: Employee; Self; Sanofi. D. Mauricio: None.

Funding

Sanofi

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.